Urispas 200mg film-coated tablets

  • Name:

    Urispas 200mg film-coated tablets

  • Company:
    info
  • Active Ingredients:

    Flavoxate Hydrochloride, Lactose

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 27/11/18

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 9/8/2019

Click on this link to Download PDF directly

Recordati Ireland Limited

Recordati Ireland Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Betaloc 1 mg/ml Solution for Injection Active Ingredients Metoprolol Tartrate
Medicine Name Citrafleet Active Ingredients Citric Acid (Anhydrous), Magnesium Oxide Light, Sodium picosulfate
Medicine Name Cleenema Ready-to-Use 21.4g / 9.4g Enema Active Ingredients Disodium Phosphate Dodecahydrate, Sodium Dihydrogen Phosphate Dihydrate
Medicine Name Kentera oxybutynin transdermal patch Active Ingredients Oxybutynin
Medicine Name Lercaril 10 mg/10 mg Film-coated Tablets Active Ingredients Enalapril Maleate, Lercanidipine Hydrochloride
Medicine Name Lercaril 20 mg/10 mg Film-coated Tablets Active Ingredients Enalapril Maleate, Lercanidipine Hydrochloride
Medicine Name Lercaril 20 mg/20 mg Film-coated Tablets Active Ingredients Enalapril Maleate, Lercanidipine Hydrochloride
Medicine Name Phospho-soda 24.4g / 10.8g oral solution Active Ingredients Disodium Phosphate Dodecahydrate, Sodium Dihydrogen Phosphate Dihydrate
Medicine Name Reagila 1.5 mg hard capsules Active Ingredients Cariprazine hydrochloride
Medicine Name Reagila 3 mg hard capsules Active Ingredients Cariprazine hydrochloride
Medicine Name Reagila 4.5 mg hard capsules Active Ingredients Cariprazine hydrochloride
Medicine Name Reagila 6 mg hard capsules Active Ingredients Cariprazine hydrochloride
Medicine Name Urispas 200mg film-coated tablets Active Ingredients Flavoxate Hydrochloride, Lactose
Medicine Name Urorec 4 mg capsules Active Ingredients Silodosin
Medicine Name Urorec 8 mg capsules Active Ingredients Silodosin
Medicine Name Urorec capsules Active Ingredients Silodosin
Medicine Name Vitaros 3mg/g Cream Active Ingredients Alprostadil
Medicine Name Zanidip 10mg and 20mg Tablets Active Ingredients Lercanidipine Hydrochloride
Medicine Name Zanidip 10mg Tablets Active Ingredients Lercanidipine Hydrochloride
Medicine Name Zanidip 20mg Tablets Active Ingredients Lercanidipine Hydrochloride
1 - 0 of 20 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 9 August 2019 SmPC

Reasons for updating

  • File format updated to PDF

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 27 November 2018 PIL

Reasons for updating

  • Previous version of PIL reinstated

Updated on 29 May 2018 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 21 October 2014 PIL

Reasons for updating

  • New PIL for new product

Updated on 21 October 2014 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 21 October 2014 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

SPC updated to include change in ADR reporting details from IMB to HPRA details
Revision date updated

Updated on 21 October 2014 PIL

Reasons for updating

  • Addition of information on reporting a side effect.

Updated on 5 March 2013 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.2 Posology & Method of Administration: Inserted "Paediatric Population: Urispas should not be used in children younger than 12 years of age."
Deleted: "Children: Urispas tablets are not recommended for children under 12 years of age."

Section 4.3 Contraindications
Deleted "of Urispas" and inserted "listed in section 6.1."

Section 4.5 Interactions with other medicinal products and other forms of interaction
Deleted "none known" and inserted "No interaction studies have been performed."

Section 4.7 Effects on the ability to drive and on use of machines
Inserted "Patients should be informed about the possible occurrence"...and "should be cautioned about driving or operating machines"

Section 4.8 Undesirable Effects
Changed layout to MedDRA system organ class and frequency.
Changed "not known" to "Not known (frequency cannot be estimated from available data)"

Section 10 Date of Revision of Text

Changed to January 2013

Updated on 5 February 2013 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to storage instructions
  • Change to side-effects
  • Change to information about pregnancy or lactation
  • Change to date of revision
  • Change to improve clarity and readability
  • Correction of spelling/typing errors

Updated on 21 February 2011 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 6.1 - List of excipients
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In Section 2 (Qualitative and Quantitative Composition), "Excipients - contains Lactose Monohydrate 64.0mg" has been added
In Section 4.6 (Pregnancy & Lactation), "Fertility" has been added to section title
In Section 6.1 (List of Excipients), "monohydrate" has been added after the word lactose - tablet core
In Section 6.5 (Nature & Contents of Container) pack sizes "250, 100, 90 or 6" has been added. "Not all pack sizes may be marketed" has also been added.
In Section 9 (Date of First Authorisation), "Date of last renewal 15OCT2010" has been added
In Section 10 (Date of Revision of Text), "21JAN2011" has been added

Updated on 15 February 2011 PIL

Reasons for updating

  • Change to packaging

Updated on 16 October 2007 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 7  The MAH is now Recordati Ireland Limited

Updated on 16 October 2007 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 11 September 2007 PIL

Reasons for updating

  • Change due to harmonisation of patient information leaflet

Updated on 21 September 2006 SmPC

Reasons for updating

  • Change to section 4.9 - Overdose

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

SPC section 4.9 -overdose statement  on gastric lavage has been updated

Updated on 20 July 2006 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

update to Immune System disorders and skin and subcutaneous tissue disorders for hypersensitivity reactions.

Updated on 20 July 2006 PIL

Reasons for updating

  • Change to side-effects

Updated on 24 May 2006 PIL

Reasons for updating

  • Change to information about driving or using machinery

Updated on 24 May 2006 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 23 February 2005 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 7 October 2004 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 6 November 2003 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 27 June 2003 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may be renewed (B)